The FDA Type C meeting outcome and LEVEL-2 enrollment restart timeline are the next catalysts. The enrichment strategy is hypothesis-generating and may not be accepted by regulators; monitor for protocol publication and FDA feedback in Q1 2027.
Drug in focus
TENX drug pipeline →levosimendan
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If LEVEL Phase 3 data is positive (Aug 2026), Tenax would need to complete a second registrational study (LEVEL-2) and file an NDA. Realistic best-case US approval would be 2028-2029, assuming positive results and a standard FDA review cycle.
- Next catalyst
- None dated
What to watchThe Phase 3 LEVEL topline readout in August 2026 is a make-or-break binary catalyst. Positive data could unlock a ~$2B+ market opportunity as the first approved therapy for PH-HFpEF, while a miss would likely devastate the stock. With a strong cash runway (~$118.8M through Q1 2028), no near-term dilution risk exists. This is a pure binary options-style biotech setup, size accordingly.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $1.63entry
- T+1 · 11d ago +3.68%α +3.37% · $1.69
- T+5 · 5d ago −1.23%α −4.52% · $1.61
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The primary news is the completion of statistical analyses from the failed Phase 3 LEVEL trial, yielding a predictive enrichment strategy being applied to the amended LEVEL-2 protocol, and a granted Type C meeting with the FDA. Cash runway extended through fiscal 2028.
Key Financial Metrics
Key Facts
- Cash and cash equivalents of $113.7M as of September 30, 2026; cash runway through fiscal 2028
- Phase 3 LEVEL trial did not meet primary endpoint; post hoc analysis identified enrichment criteria for LEVEL-2
- LEVEL-2 enrollment temporarily paused for protocol amendment to enrich for more symptomatic patients
- FDA granted a Type C meeting to discuss overall development of levosimendan in PH-HFpEF
- R&D expenses $12.1M in Q3 2026 vs $10.3M in Q3 2025
- SG&A expenses $5.7M in Q3 2026 vs $6.5M in Q3 2025
Financial Impact
Q3 net loss $16.7M; cash burn $4.3M in Q3; cash runway extended through fiscal 2028
Risk Factors
- LEVEL trial failed primary endpoint; subgroup/post hoc analyses may not be confirmed in LEVEL-2
- FDA may disagree with revised development plan or require additional trials
- Enrichment criteria may slow LEVEL-2 enrollment and reduce commercial opportunity
- Potential need for dilutive financing if cash runway assumptions change after FDA meeting
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-448517 |
| Document: d33477d8k.htm | 0001193125-26-448517 |
| Document: 0001193125-26-448517-index-headers.html | 0001193125-26-448517 |
| Document: 0001193125-26-448517-index.html | 0001193125-26-448517 |
| Document: 0001193125-26-448517.txt | 0001193125-26-448517 |
| 8-K Data (Synthetic) | 0001193125-26-448517 |
Track record
30 reports on TENX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.48 Now $1.48 +0.00% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.52 Now $1.48 −2.63% settles Dec 16
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.52 Now $1.48 +2.63% settles Dec 16
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.52 Now $1.48 +2.63% settles Dec 15
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $1.60 Now $1.48 −7.51% settles Dec 15
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.62 Now $1.48 +8.64% settles Dec 15
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $1.61 Now $1.48 −8.07% settles Dec 11
- Nov 5, 202611d ago 8-K Neutral 5/10 Viewing Entry $1.63 Now $1.48 −9.20% settles Dec 4
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $1.88 Now $1.48 −21.28% settles Nov 25
- Oct 15, 20264w ago SC 13G/A Neutral 3/10 Entry $1.36 to $1.62 Now $1.48 +8.82% ▲ +19.12% +20.28% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers